

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者	書籍名	出版社名	出版地	出版年	ページ
Hara.M. Matsuura.T <u>Kojima.S</u>	TGF-β LAP degradation products, a novel biomarker and promising therapeutic target for liver fibrogenesis.	Nakao, K., Minato, N., and Umeto, S. eds	Innovative Medicine : Basic Research and Development	Springer	Tokyo	2015	In press
<u>原田憲一</u> 中沼安二	自己免疫性肝疾患の病理診断	大平弘正 坂井田功	HEPATOLOGY PRACTICE 第4 巻	文光堂	東京	2014	50-57
<u>Kenichi</u> <u>Harada</u>	Histological Findings of Autoimmune Hepatitis	Hiromasa Ohira	Autoimmune Liver Diseases	Springer Japan	Tokyo	2014	45-65

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Aoki J, <u>Kimura K.</u> , Kakihana K, Ohashi K, Sakamaki H.	Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation.	Springer Plus	Aug 20		2014
<u>Kimura K.</u>	Should we try anti-viral therapy for hepatitis C virus infection with pyoderma gangrenosum-like lesions?	Hepatol Res	Feb;44(2)	173-5	2014

Hara.M. Matsuura.T <u>Kojima.S</u>	LAP degradation product reflects plasma kallikrein-dependent TGF- $\beta$ activation in patients with hepatic fibrosis	<i>SpringerPlus</i>	3	221	2014
Hosoya S, <u>Ikejima K</u> , Takeda K, Arai K, Ishikawa S, Yamagata H, Aoyama T, Kon K, Yamashina S, Watanabe S.	Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice	Am J Physiol Gastrointest Liver Physiol.	304	G293-9	2013
<u>Okusaka T</u> , Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y, Okita K.	A phase 1, open-label, non-randomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma	Hepatology Research			
Shiba S, <u>Okusaka T</u> . et al.	Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib.	Hepatology Research	44(13)	1268-127 6	2014
Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, <u>Okusaka T</u> , Kosuge A, Shibata T.	FGFR2 tyrosine kinase fusion define a unique molecular subtype of cholangiocarcinoma.	Hepatology,	59(4)	1427-143 4	2014
Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, <u>Okusaka T</u> , et al	Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.	Nat Genet	46(12)	1267-127 3	2014
Watanabe T, Hatakeyama H,	In vivo therapeutic potential of Dicer-hunting	Sci Rep.	23	4:4750	2014

Matsuda-Yasui C, Sato Y, Sudoh M, Takagi A, Hirata Y, Ohtsuki T, Arai M, <u>Inoue K</u> , Harashima H, Kohara M.	siRNAs targeting infectious hepatitis C virus.				
Arai M, Tsukiyama-Kohara K, Takagi A, Tobita Y, <u>Inoue K</u> , Kohara M.	Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.	Biochem Biophys Res Commun.	448(1)	56-62	2014
<u>原田 憲一</u>	肝良性腫瘍の病理診断	画像診断	35(2)	148-157	2015
Ren XS, Sato Y, <u>Harada K</u> , Sasaki M, Furubo S, Song JY, Nakanuma Y.	Activation of the PI3K/mTOR Pathway Is Involved in Cystic Proliferation of Cholangiocytes of the PCK Rat.	PLoS One.	30;9(1)	e87660. (1-14)	2014
<u>原田 憲一</u>	病理学的に肝細胞癌と鑑別を要する疾患	映像情報メデikal	46(5)	418-420	2014
<u>原田 憲一</u>	胆管癌と鑑別を要する良性胆管狭窄	病理と臨床	32(4)	446-447	2014
<u>原田 憲一</u>	良性胆管狭窄を来す胆道系炎症性疾患	石川医報	10(2)	27-29	2014
Hoshi M, <u>Osawa Y</u> , Ito H, Ohtaki H, Ando T, Takamatsu M, Hara A, Saito K, Seishima M.	Blockade of Indoleamine 2,3-Dioxygenase Reduces Mortality from Peritonitis and Sepsis in Mice by Regulating Functions of CD11b+ Peritoneal Cells.	Infect Immun.	82	4487-4495	2014.